GleamWall
中文EN

CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Services-Commercial Physical & Biological Research · NYSE · SEC CIK 1100682 · Fiscal year ends 12/27

Financial factors as of 2026-09-26 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-1.2%
TTM net income YoY148.8%
TTM EPS YoY160.5%
Revenue 3-yr CAGR-1.9%
Net income 3-yr CAGR-56.1%

Margins

Gross margin—
Operating margin4.0%
Net margin1.0%
FCF margin10.0%
EBITDA margin11.2%

Returns

ROE1.2%
ROA0.5%
ROIC (approx.)2.3%
Asset turnover0.53x

Leverage & solvency

Liabilities / assets56.0%
Debt / equity0.76x
Current ratio1.41x
Interest coverage1.45x

Cash quality & payout

Operating cash flow / net income15.49x
Accruals ratio-7.8%
Payout ratio—
Capex / revenue5.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-262026Q22026-06-272026Q12026-03-282025Q4*2025-12-272025Q32025-09-272025Q22025-06-282025Q12025-03-292024Q4*2024-12-28
Income statement
Revenue$982.73M$1.00B$995.83M$994.23M$1.00B$1.03B$984.17M$1.00B
SG&A expense$140.59M$228.90M$159.42M$196.14M$177.59M$191.55M$177.80M$195.71M
Operating income$202.64M$119.89M$119.90M-$283.44M$133.80M$100.13M$74.67M-$167.69M
Interest expense$28.52M$30.34M$26.74M$23.77M$25.40M$29.97M$27.88M$28.23M
Income tax-$163.79M$53.93M-$15.14M-$17.81M$31.64M$18.73M$10.10M-$3.04M
Net income$333.07M-$1.48M-$14.84M-$276.56M$54.42M$52.33M$25.47M-$214.50M
EBITDA$274.90M$187.18M$187.05M-$205.16M$218.96M$219.64M$195.03M-$65.58M
EPS (basic)6.97-0.03-0.30—1.111.060.50—
EPS (diluted)6.86-0.03-0.30—1.101.060.50—
Weighted avg. shares (diluted)48.58M48.02M48.95M—49.43M49.32M50.85M—
Balance sheet
Cash & equivalents$200.38M$192.03M$191.83M$213.77M$207.10M$182.82M$229.36M$205.57M
Receivables$735.30M$711.75M$700.25M$708.86M$734.48M$767.57M$756.63M$720.91M
Inventory$319.64M$346.26M$359.72M$299.10M$302.55M$279.55M$290.16M$278.54M
Current assets$1.54B$1.53B$1.49B$1.45B$1.53B$1.47B$1.51B$1.40B
PP&E, net$1.50B$1.49B$1.51B$1.66B$1.59B$1.61B$1.59B$1.60B
Goodwill$3.08B$3.08B$3.04B$2.76B$2.92B$2.94B$2.87B$2.85B
Intangibles$238.66M$253.17M$248.99M$340.00M$571.09M$602.45M$655.71M$723.40M
Total assets$7.45B$7.53B$7.73B$7.14B$7.51B$7.56B$7.58B$7.53B
Current liabilities$1.09B$1.13B$1.09B$1.12B$1.12B$1.08B$1.05B$994.10M
Short-term debt$2.10M$5.46M$6.70M$166,000$54,000$98,000$121,000$155,000
Long-term debt$2.44B$2.62B$2.66B$2.14B$2.19B$2.33B$2.51B$2.24B
Total debt$2.45B$2.63B$2.67B$2.14B$2.19B$2.33B$2.51B$2.24B
Total liabilities$4.18B$4.64B$4.74B$3.92B$4.06B$4.16B$4.34B$4.02B
Shareholders' equity$3.23B$2.84B$2.94B$3.16B$3.41B$3.35B$3.19B$3.46B
Net debt$2.25B$2.43B$2.48B$1.92B$1.98B$2.15B$2.28B$2.03B
Shares outstanding47.88M47.73M48.17M49.22M49.22M49.21M49.12M51.14M
Cash flow statement
Operating cash flow$254.09M$179.72M$41.08M$147.52M$213.83M$204.60M$171.70M$159.36M
Capital expenditure$46.81M$31.11M$55.91M$88.95M$35.58M$35.30M$59.32M$75.62M
Free cash flow$207.28M$148.62M-$14.83M$58.57M$178.25M$169.31M$112.37M$83.75M
Investing cash flow$10.23M$28.10M-$407.85M-$92.81M-$33.70M-$37.34M-$45.48M-$76.10M
Financing cash flow-$254.15M-$164.66M$347.72M-$51.86M-$152.62M-$226.92M-$105.33M-$75.88M
Depreciation & amortization$72.26M$67.29M$67.15M$78.28M$85.16M$119.51M$120.36M$102.10M
Stock-based compensation$20.77M$19.78M$22.38M$17.63M$23.27M$17.05M$13.13M$17.23M
Share buybacks$224,000$115.60M$208.28M$96,000$93,000$7.35M$353.13M$124,000

Free plan shows the latest 8 periods; Pro shows all 70 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.